AOD-9604 + Ipamorelin + CJC-1295 · fat-loss + GH stack
Three-component fat-loss stack. AOD-9604 for direct lipolysis; ipamorelin + CJC-1295 for endogenous GH pulses driving lipid oxidation. Common in body-composition protocols.
Mechanism rationale
AOD-9604 is a synthetic 16-amino-acid C-terminal fragment of human GH that retains the lipolytic activity without the growth-promoting effect. Ipamorelin + CJC-1295 generates endogenous GH pulses (see ipamorelin-and-cjc-1295 stack). The rationale for stacking all three: AOD-9604 directly amplifies lipolysis, while ipamorelin/CJC-1295 trigger GH pulses that enhance lipid oxidation downstream. Some users dose AOD-9604 near visible fat depots on a localised-lipolysis theory; the evidence for site-specific effect is weak. The community-practice protocol times all three before fasted morning cardio.
Standard dose schedule
AOD-9604 250 to 500 mcg sub-q before fasted morning cardio. Ipamorelin 100 to 300 mcg + CJC-1295 100 to 200 mcg (no DAC) sub-q at the same dose-time. Cycles 8 to 12 weeks continuous, 4-week break. Reconstitution: standard 5 mg vials in 2 to 5 mL bacteriostatic water for each component.
Not medical advice. Reconstitution math at /tools/reconstitution-calculator.
The honest read
AOD-9604 has small-trial data (Metabolic Pharmaceuticals; modest fat-loss effect, no significant adverse events at standard dose). Ipamorelin + CJC-1295 individual trial data exists. Combined stack data is essentially absent in formal trials. Community fat-loss reports are positive but heavily confounded by training + diet variables; the specific contribution of the stack is hard to isolate. The honest read: small effect on top of caloric deficit + training, not a substitute for either.
What both compounds share
GH-axis activation has the same long-term theoretical cancer-promotion concern as ipamorelin-and-cjc-1295 alone. AOD-9604 is hGH-derived and triggers the same WADA prohibited-list flag for competitive athletes. Insulin sensitivity decrease at the upper dose ranges. Carpal tunnel + edema reported at high doses. Pregnancy + breastfeeding off-limits. Pre-existing cancer is a hard contraindication.
Related Panya answers
Probably not. Sumithran 2008 Phase 2b in 537 obese adults at four doses failed to differentiate from placebo over 24 weeks. The compound is still sold as a fat-loss peptide but the...
Documented adult GH deficiency: yes under medical supervision. Sleep + body comp + recovery in healthy adults: ipamorelin + CJC-1295 (no DAC) nightly at 250-300 mcg has community s...
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.
Last reviewed 2026-04-29. Stack pages refresh when literature, supply, or community practice shifts materially. Email partner@panya.health if you spot something we have wrong.